Cardiovascular Risk Biomarkers Found for JSLE Patients
By LabMedica International staff writers Posted on 25 Jun 2019 |
Image: Lupus Erythematosus (LE) Cells are neutrophils that have engulfed lymphocyte nuclei coated with and denatured by antibody to nucleoprotein (Photo courtesy of Dr. Moustafa Abdou).
Systemic lupus erythematosus is an autoimmune disease typically affecting women between the ages of 15 and 50, and symptoms flare up unpredictably. Approximately 20% of cases begin during childhood and in these patients the disease is suggested to be more severe.
Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune dysregulation, chronic inflammation and increased cardiovascular risk (CVR). Cardiovascular disease is the leading cause of mortality in JSLE not attributable to lupus flare. Symptoms of this diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
A team of scientists working with the University College London (London, UK) to investigated dyslipidemia and CVR in a cohort of JSLE patients using in depth metabolomics and related this to clinical and immune cell profiles and to identify novel biomarkers to predict CVR in these patients. Metabolic biomarker analysis by Nuclear Magnetic Resonance (NMR) and in-depth immune cell phenotyping (30 subsets by flow cytometry) was performed on serum and peripheral blood mononuclear cells (PBMCs) respectively from a discovery cohort of 35 JSLE patients (median age 19 (14-25), 12 males, 23 females) compared with 39 age/sex matched healthy donors (HCs) (median age 18 (16-25), 17 males, 22 females).
The team reported that patient stratification by metabolomic profile using unbiased hierarchical clustering revealed three groups that each had a unique lipoprotein profile, immune cell phenotype and clinical presentation. Group-1 had decreased atheroprotective high-density lipoproteins (HDL) and increased atherogenic very low and low-density lipoproteins (VLDL/LDL). Group-2 had elevated HDL, but reduced VLDL/LDL indicating that these groups could be at high and low CVR respectively. Patients in Group-3 displayed an intermediate CVR but a pro-inflammatory immune cell profile.
Patients in Group-1 had a significant increase in plasmablasts and activated T-cells compared to HCs and had clinical features associated with increased disease activity. This metabolomic patient stratification was validated in a separate JSLE cohort. Importantly ApoB:A1 ratio was identified as a highly predictive biomarker distinguishing between JSLE patients in Group-1 and 2, indicating high and low CVR respectively. Finally, longitudinal analysis revealed that the ApoB:A1 ratio biomarker remained stable over time.
George A. Robinson, PhD, a senior research associate and co-author of the study, said, “Our study identifies ApoB:A1 ratio and metabolomic lipoprotein signatures as potential new biomarkers to predict cardiovascular risk in patients with juvenile-onset SLE. Patient stratification using these biomarkers could provide an opportunity for tailored disease treatments using lipid modification therapy and lifestyle interventions.” The study was presented at the Annual European Congress of Rheumatology held June 12-15, 2019, in Madrid, Spain.
Related Links:
University College London
Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune dysregulation, chronic inflammation and increased cardiovascular risk (CVR). Cardiovascular disease is the leading cause of mortality in JSLE not attributable to lupus flare. Symptoms of this diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
A team of scientists working with the University College London (London, UK) to investigated dyslipidemia and CVR in a cohort of JSLE patients using in depth metabolomics and related this to clinical and immune cell profiles and to identify novel biomarkers to predict CVR in these patients. Metabolic biomarker analysis by Nuclear Magnetic Resonance (NMR) and in-depth immune cell phenotyping (30 subsets by flow cytometry) was performed on serum and peripheral blood mononuclear cells (PBMCs) respectively from a discovery cohort of 35 JSLE patients (median age 19 (14-25), 12 males, 23 females) compared with 39 age/sex matched healthy donors (HCs) (median age 18 (16-25), 17 males, 22 females).
The team reported that patient stratification by metabolomic profile using unbiased hierarchical clustering revealed three groups that each had a unique lipoprotein profile, immune cell phenotype and clinical presentation. Group-1 had decreased atheroprotective high-density lipoproteins (HDL) and increased atherogenic very low and low-density lipoproteins (VLDL/LDL). Group-2 had elevated HDL, but reduced VLDL/LDL indicating that these groups could be at high and low CVR respectively. Patients in Group-3 displayed an intermediate CVR but a pro-inflammatory immune cell profile.
Patients in Group-1 had a significant increase in plasmablasts and activated T-cells compared to HCs and had clinical features associated with increased disease activity. This metabolomic patient stratification was validated in a separate JSLE cohort. Importantly ApoB:A1 ratio was identified as a highly predictive biomarker distinguishing between JSLE patients in Group-1 and 2, indicating high and low CVR respectively. Finally, longitudinal analysis revealed that the ApoB:A1 ratio biomarker remained stable over time.
George A. Robinson, PhD, a senior research associate and co-author of the study, said, “Our study identifies ApoB:A1 ratio and metabolomic lipoprotein signatures as potential new biomarkers to predict cardiovascular risk in patients with juvenile-onset SLE. Patient stratification using these biomarkers could provide an opportunity for tailored disease treatments using lipid modification therapy and lifestyle interventions.” The study was presented at the Annual European Congress of Rheumatology held June 12-15, 2019, in Madrid, Spain.
Related Links:
University College London
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms